Investors Buy Shares of DexCom Inc. (DXCM) on Weakness on Insider Selling
Traders purchased shares of DexCom Inc. (NASDAQ:DXCM) on weakness during trading on Friday following insider selling activity. $62.16 million flowed into the stock on the tick-up and $19.34 million flowed out of the stock on the tick-down, for a money net flow of $42.82 million into the stock. Of all companies tracked, DexCom had the 13th highest net in-flow for the day. DexCom traded down ($2.84) for the day and closed at $92.96Specifically, insider Terrance H. Gregg sold 10,740 shares of the stock in a transaction dated Thursday, September 8th. The shares were sold at an average price of $95.29, for a total transaction of $1,023,414.60. Following the completion of the transaction, the insider now directly owns 451,486 shares of the company’s stock, valued at $43,022,100.94. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Andrew K. Balo sold 55,000 shares of the stock in a transaction dated Monday, June 20th. The stock was sold at an average price of $75.00, for a total transaction of $4,125,000.00. Following the transaction, the executive vice president now directly owns 184,979 shares of the company’s stock, valued at $13,873,425. The disclosure for this sale can be found here. Corporate insiders own 2.80% of the company’s stock.
A number of research analysts have issued reports on the stock. Benchmark Co. dropped their target price on shares of DexCom from $106.00 to $86.00 and set a “buy” rating for the company in a report on Wednesday, August 3rd. Jefferies Group reaffirmed a “positive” rating and issued a $98.00 target price on shares of DexCom in a report on Friday, July 22nd. Zacks Investment Research raised shares of DexCom from a “sell” rating to a “hold” rating in a report on Tuesday, July 19th. Deutsche Bank AG increased their target price on shares of DexCom from $90.00 to $98.00 and gave the company a “buy” rating in a report on Friday, July 15th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $112.00 target price on shares of DexCom in a report on Wednesday, June 15th. Three equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $93.82.
The firm has a 50-day moving average price of $91.20 and a 200-day moving average price of $74.23. The company’s market cap is $7.80 billion.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/10/investors-buy-shares-of-dexcom-inc-dxcm-on-weakness-on-insider-selling.html
DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Tuesday, August 2nd. The medical device company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by $0.12. DexCom had a negative return on equity of 19.68% and a negative net margin of 16.42%. The company had revenue of $137.30 million for the quarter, compared to the consensus estimate of $132.48 million. During the same quarter last year, the firm posted ($0.05) earnings per share. The firm’s quarterly revenue was up 47.3% compared to the same quarter last year. On average, analysts expect that DexCom Inc. will post ($0.57) EPS for the current year.
DexCom Company Profile
Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers for the treatment of people with and without diabetes. Its products include SEVEN PLUS, DexCom G4, DexCom G4 PLATINUM, DexCom Share System and DexCom G5 Mobile.
Receive News & Ratings for DexCom Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for DexCom Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.